Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:46:42 2024-03-28 am EDT 5-day change 1st Jan Change
5.125 USD +4.59% Intraday chart for Black Diamond Therapeutics, Inc. -6.19% +80.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board CI
Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535 CI
Black Diamond Therapeutics, Inc. Announces Management Changes CI
Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes CI
Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer CI
Certain Restricted Stock Units of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023. CI
Certain Warrants of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023. CI
Certain Stock Options of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023. CI
Certain Common Stock of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023. CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target MT
Sector Update: Health Care Stocks Steady Premarket Monday MT
Black Diamond Therapeutics Discloses Institutional Shareholder Equity Stake Expansion; Shares Jump Premarket MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2 MT
Black Diamond Therapeutics Prices $75 Million Common Stock Offering MT
Top Premarket Decliners MT
Black Diamond Therapeutics Launches $75 Million Stock Offering; Shares Drop After-Hours MT
Insider Sell: Black Diamond Therapeutics MT
HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11 MT
Sector Update: Health Care Stocks Softer Late Tuesday MT
Sector Update: Health Care Stocks Easing Tuesday Afternoon MT
Chart Black Diamond Therapeutics, Inc.
More charts
Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company is focused on the discovery and development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Its technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. The Company's lead product candidate, BDTX-1535 is a brain-penetrant inhibitor that targets a spectrum of epidermal growth factor receptor (EGFR) mutations, including allosteric and canonical mutations. Its second product candidate, BDTX-4933, is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic B-Raf Proto-Oncogene (BRAF) Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations, such as rat sarcoma virus (RAS) mutations, which has the potential to avoid paradoxical activation.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.9 USD
Average target price
10.6 USD
Spread / Average Target
+116.33%
Consensus
  1. Stock
  2. Equities
  3. Stock Black Diamond Therapeutics, Inc. - Nasdaq
  4. News Black Diamond Therapeutics, Inc.
  5. Earnings Flash (BDTX) BLACK DIAMOND THERAPEUTICS Reports Q3 Loss $-0.97